INDEPENDENT NEWS

Blis confirms Asia-Pacific and Africa distribution agreement

Published: Fri 7 Sep 2018 01:51 PM
Blis Technologies confirms Asia-Pacific and Africa distribution agreement with iNova Pharmaceuticals
7 September 2018 | Dunedin, New Zealand
Blis Technologies Limited today confirmed it has entered into a distribution agreement with iNova Pharmaceuticals (Singapore) Pte Ltd for the distribution of BLIS branded products. iNova Pharmaceuticals is a multinational pharmaceutical and consumer health care company that markets and sells a wide range of market-leading products in over 20 countries across Asia-Pacific and Africa.
The agreement will provide iNova Pharmaceuticals with exclusive distribution rights for BLIS branded products across Australia, Sub-Saharan Africa, and Asia based on a commitment of resources to support product launches. iNova Pharmaceutical’s presence in pharmacy retail provides a strong platform for the launch of BLIS branded products into overseas markets.
The initial focus will be on launch plans for the Australian market where BLIS K12 has achieved inclusion in TGA’s Therapeutic Goods (Permissible Ingredients) Determination for use in listed complementary medicines, allowing stronger positioning of the BLIS portfolio.
Blis CEO Brian Watson says that this agreement is another important step in the company’s finished product strategy.
“iNova Pharmaceuticals has a strong presence in the pharmacy channel and a proven track record of establishing category-leading brands in consumer health care. Working with a partner of this calibre will provide the right capability and resourcing to effectively establish BLIS branded products in multiple markets across the iNova Pharmaceuticals network. Our focus initially will be to finalise our plans for the Australian market but also to progress launch plans for other markets across Asia and Africa”
The agreement builds on the success of Blis Technologies’ new distribution relationship in New Zealand with Radiant Health, which also holds the distribution rights for the iNova Pharmaceuticals product range locally. Radiant has demonstrated its ability to leverage its presence in the market to help grow the BLIS range.
ENDS

Next in Business, Science, and Tech

Gordon Campbell on the Tax Working Group’s road map
By: Gordon Campbell
Media advisory re Australian strawberries
By: Countdown Supermarket
Broad-based growth as GDP rises 1 percent in June quarter
By: Statistics New Zealand
Judgment: NZ Steel v Minister of Consumer Affairs
By: New Zealand High Court
Tax Working Group proposes wider scope taxing capital gains
By: BusinessDesk
The Nation: Tax Working Group Chair Michael Cullen
By: The Nation
Tax Working Group publishes Interim Report
By: Tax Working Group
Feedback sought on Tax Working Group interim report
By: New Zealand Government
Govt won’t rule out tax grab on retirement savings
By: New Zealand National Party
Capital Gains Tax still hangs over NZ
By: New Zealand National Party
Robertson refuses to rule out higher taxes
By: New Zealand National Party
ACT Laments Over Tax Working Group Report
By: ACT New Zealand
Tax fixes not rocket science
By: New Zealand Council of Trade Unions
Report shows signs of extending the tax net
By: Public Service Association
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media